China Biologic Products Inc (NASDAQ:CBPO)

109.99
Delayed Data
As of May 28
 -0.15 / -0.14%
Today’s Change
37.50
Today|||52-Week Range
111.03
+63.60%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.7B

Company Description

China Biologic Products, Inc. is the non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. Through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and its equity investment in Xi'an Huitian Blood Products, the firm is a fully integrated provider of plasma-based biopharmaceuticals, with capabilities spanning from plasma collection to and research and development, to product manufacturing and commercialization. The firm's key products, human albumin and immunoglobin, are often used to treat life-threatening conditions, such as low albumin, hemophilia and other blood diseases. The firm has marketed plasma-based products and a pipeline of new products to drive future growth in the large Chinese plasma market. The company was founded on December 20, 1989 and is headquartered in Shandong Province, China.

Contact Information

China Biologic Products, Inc.
18/F, Jialong International Tower
Beijing Beijing 100125
P:861065983099
Investor Relations:

Employees

Shareholders

Individual stakeholders92.47%
Mutual fund holders7.18%
Other institutional11.77%

Top Executives

David Xiaoying GaoExecutive Chairman, President & CEO
Ming YangCFO, Treasurer & Vice President-Compliance
Yi-Wu Vincent XieChief Technology Officer
Ming YinSenior Vice President
Zhijing CBPO LiuVice President

To view my watchlist

Not a member yet?

Sign up now for a free account